Seeking Alpha

Rigel Pharmaceuticals (RIGL +6.3%) gets a bump from Roth Capital this morning, initiating the...

Rigel Pharmaceuticals (RIGL +6.3%) gets a bump from Roth Capital this morning, initiating the shares with a Buy rating and a price target of $15. Yesterday, the company announced it's commenced Phase 2 clinical studies on two of its marquee drug candidates. The first, R343, is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. The second, R333, is a topical JAK/SYK inhibitor aimed at treating various phases of lupus of the skin.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|